Yousif Capital Management LLC Sells 382 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Yousif Capital Management LLC trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,707 shares of the company’s stock after selling 382 shares during the period. Yousif Capital Management LLC’s holdings in Prestige Consumer Healthcare were worth $1,608,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in shares of Prestige Consumer Healthcare by 5.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock worth $49,667,000 after purchasing an additional 33,844 shares during the period. Norges Bank purchased a new stake in Prestige Consumer Healthcare in the 4th quarter worth about $40,009,000. BNP Paribas Financial Markets increased its holdings in Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company’s stock worth $15,923,000 after acquiring an additional 186,524 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Prestige Consumer Healthcare by 14.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company’s stock worth $649,000 after acquiring an additional 1,030 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Prestige Consumer Healthcare by 3.2% in the 4th quarter. Principal Financial Group Inc. now owns 256,526 shares of the company’s stock worth $20,032,000 after acquiring an additional 7,890 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $83.67 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare Inc. has a 1 year low of $64.03 and a 1 year high of $90.04. The stock’s 50 day simple moving average is $83.84 and its two-hundred day simple moving average is $82.53. The company has a market cap of $4.13 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 2.69 and a beta of 0.45.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. During the same quarter in the previous year, the business earned $1.02 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on PBH shares. Wall Street Zen raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 17th. Royal Bank of Canada raised Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.